+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Genomics Partnering Terms and Agreements 2014 to 2021

  • ID: 4636691
  • Report
  • December 2021
  • Region: Global
  • 600 Pages
  • CurrentPartnering
This report provides comprehensive understanding and unprecedented access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies

FEATURED COMPANIES

  • Abbvie
  • Cell Line Genetics
  • Eisai
  • Google
  • Mercachem
  • SunTerra Biotechnology
The Global Genomics Partnering Terms and Agreements 2014 to 2021 report provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in Genomics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Genomics partnering contract documents
  • Top Genomics deals by value

The Global Genomics Partnering Terms and Agreements report provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Genomics dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Genomics deals since 2014. Deals are listed by headline value, signed by big pharma, most active Genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Genomics dealmaking with a brief summary followed by a comprehensive listing of Genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Genomics partnering company A-Z, deal type definitions and Genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genomics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genomics technologies and products.

Report Scope


Global Genomics Partnering Terms and Agreements 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Genomics trends and structure of deals entered into by leading companies worldwide.

Global Genomics Partnering Terms and Agreements 2014 to 2021 includes:

  • Trends in Genomics dealmaking in the biopharma industry since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1100 Genomics deal records and contract documents where available
  • The leading Genomics deals by value since 2014
  • Most active Genomics dealmakers since 2014
  • The leading Genomics partnering resources

In Global Genomics Partnering Terms and Agreements 2014 to 2021, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Key Benefits

Global Genomics Partnering Terms and Agreements 2014 to 2021 provides the reader with the following key benefits:


  • In-depth understanding of Genomics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to Genomics deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Genomics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Genomics deals by value since 2014
  • Identify the most active Genomics dealmakers since 2014
  • Detailed access to actual Genomics contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Genomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • Cell Line Genetics
  • Eisai
  • Google
  • Mercachem
  • SunTerra Biotechnology

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in Genomics dealmaking
2.1. Introduction
2.2. Genomics partnering over the years
2.3. Most active Genomics dealmakers
2.4. Genomics partnering by deal type
2.5. Genomics partnering by therapy area
2.6. Deal terms for Genomics partnering
2.6.1 Genomics partnering headline values
2.6.2 Genomics deal upfront payments
2.6.3 Genomics deal milestone payments
2.6.4 Genomics royalty rates
Chapter 3 - Leading Genomics deals
3.1. Introduction
3.2. Top Genomics deals by value
Chapter 4 - Most active Genomics dealmakers
4.1. Introduction
4.2. Most active Genomics dealmakers
4.3. Most active Genomics partnering company profiles
Chapter 5 - Genomics contracts dealmaking directory
5.1. Introduction
5.2. Genomics contracts dealmaking directory
Chapter 6 - Genomics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Genomics deals by company A-Z
Appendix 2 - Genomics deals by stage of development
Appendix 3 - Genomics deals by deal type
Appendix 4 - Genomics deals by therapy area
Appendix 5 -Deal type definitions
Table of Figures
Figure 1: Genomics partnering since 2014
Figure 2: Active Genomics dealmaking activity sincce 2014
Figure 3: Genomics partnering by deal type since 2014
Figure 4: Genomics partnering by disease type since 2014
Figure 5: Genomics partnering by industry sector since 2014
Figure 6: Genomics deals with a headline value
Figure 7: Genomics deals with an upfront value
Figure 8: Genomics deals with a milestone value
Figure 9: Genomics deals with a royalty rate value
Figure 10: Top Genomics deals by value since 2014
Figure 11: Most active Genomics dealmakers since 2014
Figure 12: Genomics partnering by technology type since 2014
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • DecisionQ
  • PathGroup
  • Transcriptic
  • Ambry Genetics
  • Centauri Therapeutics
  • Corteva Agriscience
  • SunTerra Biotechnology
  • Cell Line Genetics
  • Abbvie
  • Genomenon
  • Oxford Genetics
  • CardioDx
  • Charles River Laboratories
  • Arcadia Biosciences
  • Google
  • Advaita
  • Ceres
  • Vivo Biosciences
  • Nebula Genomics
  • Structural Genomics Consortium
  • Immuno Diagnostic
  • Mercachem
  • Perthera
  • Adaptive Biotechnologies
  • St Georges University of London
  • HTG Molecular Diagnostics
  • Vitaccess
  • Aptorum Group
  • National Institute of Standards and Technology
  • Genomind
  • DefiniGEN
  • Intrexon
  • Knight Diagnostic Laboratories
  • iBio
  • Emory University
  • Center for Molecular Medicine
  • Cellectis Bioresearch
  • Genomics
  • Eisai
  • University of Cincinnati
  • Plant Bioscience Limited
  • Tekmira Pharmaceuticals
  • NCIC Clinical Trials Group
  • Oncology Research Information Exchange Network
  • Janssen Pharmaceuticals
  • European Union
  • University of Montreal
  • Oncodesign
  • Helomics
  • Fujitsu Laboratories
Note: Product cover images may vary from those shown
  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...